Management of COVID-19 Coagulopathy in a Patient with Severe Haemophilia A

A 54-year-old man with a long history of severe haemophilia A treated prophylactically with efmoroctocog alpha (3,000 IU twice weekly) was diagnosed with COVID-19 infection. He had multiple risk factors for COVID-19 severity including obesity, diabetes mellitus and hypertension. He required prolonged intensive care unit (ICU) stay due to the severity of respiratory failure until his death on day 24. During his ICU stay, he received a continuous infusion of efmoroctocog alpha in order to maintain factor VIII activity between 80 and 100%, together with therapeutic doses of low-molecular-weight heparin targeting anti-Xa activity above 0.5 IU/mol. He tolerated numerous invasive procedures without bleeding. At post-mortem examination, there was no evidence for thrombosis or haemorrhage in the different organs.

Automated summary

A 54-year-old man with severe haemophilia A, also suffering from COVID-19 infection and multiple risk factors, received treatment in ICU with efmoroctocog alpha and low-molecular-weight heparin without experiencing thrombosis or hemorrhage in different organs during post-mortem examination.